Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

R Maslennikov, V Ivashkin, E Vasilieva… - Pulmonary …, 2021 - Elsevier
Background and aim Cytokine release syndrome is a dangerous complication of the
coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety …
被引用次数：43 相关文章

[引用][C] Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

R Maslennikov, V Ivashkin, E Vasilieva… - Pulmonary …, 2021 - elibrary.ru

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19.

R Maslennikov, V Ivashkin, E Vasilieva… - Pulmonary …, 2021 - europepmc.org
Methods The retrospective study included COVID-19 patients with C-reactive protein (CRP)
levels of 60-150 mg/L. Results Thirty-two patients who received tofacitinib (TOF group) and …

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

R Maslennikov, V Ivashkin, E Vasilieva, M Chipurik… - 2021 - pubmed.ncbi.nlm.nih.gov
Background and aim Cytokine release syndrome is a dangerous complication of the
coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety …
[HTML] nih.gov

[HTML][HTML] Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

R Maslennikov, V Ivashkin, E Vasilieva… - Pulmonary …, 2021 - ncbi.nlm.nih.gov
Methods The retrospective study included COVID-19 patients with C-reactive protein (CRP)
levels of 60–150 mg/L. Results Thirty-two patients who received tofacitinib (TOF group) and …

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19.

R Maslennikov, V Ivashkin, E Vasilieva… - Pulmonary …, 2021 - europepmc.org
Methods The retrospective study included COVID-19 patients with C-reactive protein (CRP)
levels of 60-150 mg/L. Results Thirty-two patients who received tofacitinib (TOF group) and …